Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Tran, B.; Horvath, L.; Dorff, T.; Rettig, M.; Lolkema, M. P.; Machiels, J. P.; Rottey, S.; Autio, K.; Greil, R.; Adra, N.; Lemech, C.; Minocha, M.; Cheng, F. C.; Kouros-Mehr, H.; Fizazi, K. |
| Abstract Title: | Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S507 |
| Language: | English |
| ACCESSION: | WOS:000573469100607 |
| DOI: | 10.1016/j.annonc.2020.08.869 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 609O -- Source: Wos |
